A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Public ClinicalTrials.gov record NCT04625270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Study identification
- NCT ID
- NCT04625270
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 225 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2020 (Actual)
- Primary completion
- Nov 15, 2024 (Actual)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Jan 29, 2025
2020 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates PC HAL | Scottsdale | Arizona | 85258 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Yale School of Medicine | New Haven | Connecticut | 06510 | — |
| Advent Health | Orlando | Florida | 32804 | — |
| H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology | Tampa | Florida | 33612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Maryland Oncology and Hematology, P.A. | Glenn Dale | Maryland | 20769 | — |
| Minnesota Oncology Hematology PA | Minneapolis | Minnesota | 55404 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87131 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Cleveland Clinic Women's Health Institute | Cleveland | Ohio | 44195 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43212 | — |
| University of Oklahoma Medical Center | Oklahoma City | Oklahoma | 73104 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Northwest Cancer Specialists | Portland | Oregon | 97227 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology- Dallas Presbyterian Hospital | Dallas | Texas | 75231 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Texas Oncology | Longview | Texas | 75601 | — |
| Texas Oncology | McAllen | Texas | 78503 | — |
| Texas Oncology | San Antonio | Texas | 78240 | — |
| Texas Oncology | The Woodlands | Texas | 77380 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists, PC | Gainesville | Virginia | 20155 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04625270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04625270 live on ClinicalTrials.gov.